A selective decoy-doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect
Journal
Chemical Communications
Journal Volume
51
Journal Issue
68
Pages
13309-13312
Date Issued
2015
Author(s)
Abstract
A novel selective decoy oligodeoxynucleotide (dODN)-doxorubicin (DOX) complex is reported for cancer theranostics. It eliminates the use of a ligand or carrier for targeted delivery and disassembles into therapeutic dODN and DOX upon encountering over-activated STAT3 in cancer cells. Hence, in situ STAT3 probing and synergistic anti-cancer effect are attained at the same time. ? 2015 Royal Society of Chemistry.
SDGs
Other Subjects
aptamer; bovine serum albumin; doxorubicin; lipofectamine; oligodeoxynucleotide; quantum dot; STAT3 protein; streptavidin; antineoplastic agent; doxorubicin; drug carrier; fluorescent dye; lipid; oligodeoxyribonucleotide; STAT3 protein; STAT3 protein, human; antineoplastic activity; apoptosis; Article; binding affinity; binding competition; cancer cell; cell death; circular dichroism; competitive binding assay; drug potentiation; drug release; fluorescence microscopy; liposomal delivery; malignant neoplastic disease; MCF 7 cell line; protein binding; ultraviolet spectroscopy; antagonists and inhibitors; chemistry; HepG2 cell line; human; theranostic nanomedicine; Antineoplastic Agents; Doxorubicin; Drug Carriers; Fluorescent Dyes; Hep G2 Cells; Humans; Lipids; MCF-7 Cells; Oligodeoxyribonucleotides; STAT3 Transcription Factor; Theranostic Nanomedicine
Type
journal article